Diamedica Therapeutics INC 10-Q quarterly reports

DiaMedica Therapeutics Inc. reported increased operating expenses and ongoing challenges with clinical trial site activations and enrollment in its ReMEDy2 trial for acute ischemic stroke.

DiaMedica Therapeutics reports on progress in its DM199 clinical trials for preeclampsia and acute ischemic stroke, while continuing to incur operating losses and seeking additional financing.

DiaMedica Therapeutics appoints Dr. Julie Krop as Chief Medical Officer, reports increased net loss and cash burn, but positive interim PE trial data and successful capital raise.

DiaMedica Therapeutics reports increased losses in Q2 2025, positive interim data for its preeclampsia trial, but faces continued enrollment delays in its acute ischemic stroke study.

DiaMedica Therapeutics reports a net loss of $7.7 million for Q1 2025 and provides updates on its preeclampsia and acute ischemic stroke clinical programs.

DiaMedica Therapeutics reported its Q3 2024 financial results and provided updates on its ongoing clinical trials for DM199, including expansion into preeclampsia.

DiaMedica Therapeutics reported its Q2 2024 financial results, highlighting progress in its ReMEDy2 trial for acute ischemic stroke and expansion into preeclampsia treatment.

DiaMedica Therapeutics reported a net loss of $5.2 million for the first quarter of 2024, while continuing to advance its ReMEDy2 clinical trial for acute ischemic stroke.